Acquisition and Stockholders' Equity (Deficit) (Details 6) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2012	Aug. 17, 2012	Feb. 04, 2014	Dec. 31, 2013
Acquisition and Stockholders' Equity (Deficit)
Purchased in-process research and development		$ 1,000,000
Gross proceeds	3,224,000
Derivative liabilities related to Warrants	172,000				1,534,000
Bristol-Myers Squibb Company | Asset Purchase Agreement
Acquisition and Stockholders' Equity (Deficit)
Initial payment in terms of agreement			1,000,000
Milestone of aggregate net sales			125,000,000
Purchased in-process research and development		1,000,000
ContraVir Subsidiary | February 4, 2014 Private Placement
Acquisition and Stockholders' Equity (Deficit)
Gross proceeds				3,200,000
Expenses related to private placement				15,000
Number of units sold (in shares)				9,485,294
Number of shares of common stock per unit				1
Number of warrants per unit (in shares)				1
Number of common shares that can be acquired upon exercise of each warrant				0.5
Purchase price (in dollars per unit)				$ 0.34
ContraVir Subsidiary | February 4, 2014 Private Placement | Warrants
Acquisition and Stockholders' Equity (Deficit)
Non-public warrants outstanding (in shares)				4,700,000
Expiration period of warrant				6 years
Exercise price of warrants (in dollars per share)				$ 0.37
Derivative liabilities related to Warrants				$ 880,000